ES2126331T3 - Conjugados de bdnf y nt-3 con un polimero soluble en agua. - Google Patents

Conjugados de bdnf y nt-3 con un polimero soluble en agua.

Info

Publication number
ES2126331T3
ES2126331T3 ES95939123T ES95939123T ES2126331T3 ES 2126331 T3 ES2126331 T3 ES 2126331T3 ES 95939123 T ES95939123 T ES 95939123T ES 95939123 T ES95939123 T ES 95939123T ES 2126331 T3 ES2126331 T3 ES 2126331T3
Authority
ES
Spain
Prior art keywords
water soluble
soluble polymer
bdnf
conjugates
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95939123T
Other languages
English (en)
Inventor
Olaf F Kinstler
Qiao Yan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ES2126331T3 publication Critical patent/ES2126331T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/839—Nerves; brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Treatment Of Sludge (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Detergent Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE HAN PREPARADO DERIVADOS DE FACTORES NEUROTROFICOS BDNF Y NT3 MEDIANTE INCORPORACION DE ESTOS POLIPEPTIDOS A UN POLIMERO SOLUBLE EN AGUA, POR EJEMPLO, POLIETILENGLICOL.
ES95939123T 1994-11-14 1995-11-13 Conjugados de bdnf y nt-3 con un polimero soluble en agua. Expired - Lifetime ES2126331T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/340,131 US5770577A (en) 1994-11-14 1994-11-14 BDNF and NT-3 polypeptides selectively linked to polyethylene glycol

Publications (1)

Publication Number Publication Date
ES2126331T3 true ES2126331T3 (es) 1999-03-16

Family

ID=23332020

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95939123T Expired - Lifetime ES2126331T3 (es) 1994-11-14 1995-11-13 Conjugados de bdnf y nt-3 con un polimero soluble en agua.

Country Status (22)

Country Link
US (1) US5770577A (es)
EP (1) EP0792288B1 (es)
JP (1) JPH10508853A (es)
KR (1) KR100253762B1 (es)
CN (1) CN1173183A (es)
AT (1) ATE175973T1 (es)
AU (1) AU694589B2 (es)
CA (1) CA2204640C (es)
CZ (1) CZ137597A3 (es)
DE (1) DE69507507T2 (es)
DK (1) DK0792288T3 (es)
ES (1) ES2126331T3 (es)
GR (1) GR3029790T3 (es)
HU (1) HUT77747A (es)
IL (1) IL115965A (es)
MX (1) MX9703362A (es)
NO (1) NO972176L (es)
NZ (1) NZ296452A (es)
RU (1) RU2136694C1 (es)
SK (1) SK283083B6 (es)
WO (1) WO1996015146A1 (es)
ZA (1) ZA959653B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JPH10212241A (ja) * 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Ｂｄｎｆを安定に含有する製剤
AU720232B2 (en) 1996-07-19 2000-05-25 Amgen, Inc. Analogs of cationic proteins
EP1126869B1 (en) * 1998-10-28 2008-09-03 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using the trk receptor ligands bdnf, nt-3 and nt-4
US6656474B1 (en) * 1999-01-15 2003-12-02 Regeneron Pharmaceuticals, Inc. Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
RU2290411C2 (ru) * 2000-01-10 2006-12-27 Максиджен Холдингз Лтд Конъюгаты g-csf
US6800607B2 (en) * 2000-02-29 2004-10-05 Ltt Bio-Pharma Co., Ltd. Modified BDNF
US7514239B2 (en) * 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
PL211162B1 (pl) * 2001-02-01 2012-04-30 Biogen Idec Inc Polipeptyd wariantu neublastyny, zawierające go białko fuzyjne i sposób ich wytwarzania oraz dimer, kwas nukleinowy, wektor, komórka gospodarza, koniugat, kompozycja farmaceutyczna i zastosowanie
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
WO2002069232A2 (en) 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
RU2307126C2 (ru) * 2001-07-11 2007-09-27 Максиджен Холдингз Лтд. Конъюгаты g-csf
CN1671769B (zh) * 2002-07-24 2010-05-12 弗·哈夫曼-拉罗切有限公司 聚乙二醇醛衍生物
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
RS20050502A (sr) * 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polimerni konjugati interferona- beta sa povećanom biološkom aktivnošću
PL396711A1 (pl) * 2002-12-26 2011-12-19 Mountain View Pharmaceuticals, Inc. Koniugaty polimerów z cytokinami, chemokinami, czynnikami wzrostu, hormonami polipeptydowymi i ich antagonistami, kompozycja farmaceutyczna i sposób zapobiegania, diagnozowania lub leczenia
PL383683A1 (pl) * 2003-01-31 2008-04-14 Biogen Idec Ma Inc. Koniugaty polimerowe zmutowanej neublastyny
EP2902491A1 (en) 2003-03-19 2015-08-05 Biogen MA Inc. NOGO receptor binding protein
JP4742030B2 (ja) 2003-04-18 2011-08-10 バイオジェン・アイデック・エムエイ・インコーポレイテッド ポリマーが結合したグリコシル化ニューブラスチン
JP2007523196A (ja) * 2004-02-20 2007-08-16 ライナット ニューロサイエンス コーポレイション Ｎｔ−４／５を用いて肥満または糖尿病を処置する方法
EP1776136B1 (en) 2004-06-24 2012-10-03 Biogen Idec MA Inc. Treatment of conditions involving demyelination
ATE472333T1 (de) 2004-08-19 2010-07-15 Biogen Idec Inc Rückfaltung von proteinen der transforming-growth-factor-beta-familie
JP4852545B2 (ja) * 2004-08-19 2012-01-11 バイオジェン・アイデック・エムエイ・インコーポレイテッド ニューブラスチン（Ｎｅｕｂｌａｓｔｉｎ）変異体
GT200600240A (es) 2005-06-06 2007-03-14 Anticuerpos monoclonales anti-trkb y usos de los mismos
AU2006269458B2 (en) 2005-07-08 2012-11-08 Biogen Ma Inc. Sp35 antibodies and uses thereof
ITRM20050447A1 (it) * 2005-08-19 2007-02-20 Anabasis S R L Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson.
US7935342B2 (en) * 2006-02-02 2011-05-03 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkB antagonist
EP1988923A1 (en) * 2006-02-02 2008-11-12 Rinat Neuroscience Corp. Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
ES2450065T3 (es) * 2006-03-01 2014-03-21 Biogen Idec Ma Inc. Composiciones y métodos para la administración de proteínas de la familia de ligandos del GDNF
US8377448B2 (en) * 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
WO2007133811A2 (en) * 2006-05-15 2007-11-22 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
BRPI0720473A2 (pt) * 2006-12-20 2014-01-14 Rinat Neuroscience Corp Agonistas de trkb para tratamento de distúbios autoimunes
JP5583005B2 (ja) 2007-05-01 2014-09-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管新生を増大させるための組成物および方法
EP2205634A2 (en) * 2007-08-08 2010-07-14 Biogen Idec MA, Inc. Anti-neublastin antibodies and uses thereof
CA2701189C (en) * 2007-10-11 2017-05-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists
JP5754046B2 (ja) * 2007-11-08 2015-07-22 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 脱髄を伴う状態の治療におけるｌｉｎｇｏ−４アンタゴニストの使用
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
RU2013103763A (ru) 2010-07-02 2014-08-10 Ангиохем Инк. Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения
NZ702178A (en) 2012-05-14 2017-01-27 Biogen Ma Inc Lingo-2 antagonists for treatment of conditions involving motor neurons
CN102964442B (zh) * 2012-11-19 2015-04-29 未名生物医药有限公司 一种聚乙二醇同神经生长因子结合物的制备方法
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
CN111514279B (zh) * 2020-06-16 2023-07-18 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 神经营养因子3在制备治疗男性性腺功能减退症的药物中的应用
CN115025723A (zh) * 2022-05-10 2022-09-09 吉林大学 经神经生长因子及多巴胺改良的peg-plga微球

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US5169762A (en) * 1983-03-03 1992-12-08 Genentech, Inc. Human nerve growth factor by recombinant technology
EP0154316B1 (en) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
JP2989002B2 (ja) * 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5180820A (en) * 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
IL95511A (en) * 1989-08-30 2000-10-31 Max Planck Gesellschaft Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
DK0550665T3 (da) * 1990-09-25 1996-12-02 Genentech Inc Ny neurotrofisk faktor
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5389529A (en) * 1991-06-12 1995-02-14 Regeneron Pharmaceuticals, Inc. Modified lamβ signal sequence and processes for producing recombinant neurotrophins
NZ244778A (en) * 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
US5260308A (en) * 1991-11-06 1993-11-09 Mayo Foundation For Medical Education And Research Method to increase permeability of the blood-nerve/brain barriers to proteins
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders

Also Published As

Publication number Publication date
ZA959653B (en) 1997-08-26
NO972176L (no) 1997-07-14
JPH10508853A (ja) 1998-09-02
SK283083B6 (sk) 2003-02-04
NO972176D0 (no) 1997-05-12
DE69507507T2 (de) 1999-05-27
CA2204640A1 (en) 1996-05-23
MX9703362A (es) 1997-08-30
SK57197A3 (en) 1999-02-11
AU4107196A (en) 1996-06-06
IL115965A (en) 2001-01-28
CN1173183A (zh) 1998-02-11
HUT77747A (hu) 1998-07-28
NZ296452A (en) 1999-01-28
CA2204640C (en) 2001-01-09
EP0792288A1 (en) 1997-09-03
IL115965A0 (en) 1996-01-31
RU2136694C1 (ru) 1999-09-10
WO1996015146A1 (en) 1996-05-23
KR100253762B1 (ko) 2000-05-01
AU694589B2 (en) 1998-07-23
CZ137597A3 (cs) 1998-10-14
DK0792288T3 (da) 1999-09-13
US5770577A (en) 1998-06-23
EP0792288B1 (en) 1999-01-20
ATE175973T1 (de) 1999-02-15
GR3029790T3 (en) 1999-06-30
DE69507507D1 (de) 1999-03-04

Similar Documents

Publication Publication Date Title
ES2126331T3 (es) Conjugados de bdnf y nt-3 con un polimero soluble en agua.
FI941434L (fi) Polymeerisäiliöitä, joilla on sulkuominaisuuksia
FI931278A0 (fi) Polymerer, som innehaoller sulfogrupper
DE69726229D1 (de) Prothese mit Flansch
FI961253A0 (fi) Virtsaputkeen tiivistyvä peitetulppa
DE69617500D1 (de) Totale Gelenkprothese mit beweglichem Lager
MY125467A (en) Olanzapine dihydrate d
DE69008954D1 (de) Einsetzbares künstliches Schliessmuskelsystem.
BR9601242A (pt) Composição de vidro de cor bronze e folha de vidro da mesma
FI940738L (fi) Elektroneja johtavia molekyylivalmisteita
BR9711949B1 (pt) sistema de telecomunicações tendo a faculdade de relocalização de número de assinante, e, processo de operar um sistema de telecomunicações.
DE69012358D1 (de) Poröse Folie.
DE68912018D1 (de) UV-härtbare Polymerzusammensetzung.
DE69707275D1 (de) Dichter elektrochemischer generator mit endschutzschalter
TR199501725A2 (tr) Sizdirmazlik düzeni.
EP0621044A3 (en) Collagen membrane.
DE69121461D1 (de) Lichtempfindliches, wärmebeständiges Polymer mit Hydroxyphenylgruppen
ITTO940416A0 (it) Cariche pigmentati per composizioni polimeriche.
FI904090A7 (fi) Kopolymeraatteja, jotka perustuvat tyydyttymättömiin radikaalisesti renkaan avaaviin keteenijohdannaisiin
FR2706285B1 (fr) Prothèse anti-luxation.
FI962120L (fi) Estramustiiniformulaatiot, joilla on parannetut farmaseuttiset ominaisuudet
EP0621623A3 (en) Double-based low pressure discharge lamp.
ES1026166Y (es) Baliza de señalizacion perfeccionada.
ITTO920282A0 (it) Composizione polimerica amidacea biodegradabile.
ES1030717Y (es) Baliza de señalizacion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 792288

Country of ref document: ES